SCHEMBL1471536

SCHEMBL1471536

Cc1ccc(C2=CC(=O)N(c3ccccc3)C2=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RGS4 P49798 1/20 0.57
ALDH1A1 P00352 6/20 0.54
MAPT P10636 5/20 0.54
NPSR1 Q6W5P4 4/20 0.54
LMNA P02545 3/20 0.54
GAA P10253 3/20 0.54
CCR6 P51684 2/20 0.54
HTT P42858 1/20 0.54
CACNA1B Q00975 3/20 0.44
APBA1 Q02410 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
MGLL Q99685 3/20 0.43
HPGD P15428 3/20 0.41
ALOX12 P18054 2/20 0.41
F2 P00734 1/20 0.41
ELANE P08246 1/20 0.41
CTSG P08311 1/20 0.41
CMA1 P23946 1/20 0.41
CTRC Q99895 1/20 0.41
FAAH O00519 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471189 0.93 ALDH1A1 (0.57) RGS4ALDH1A1MAPTNPSR1LMNA
SCHEMBL1471680 0.91 MGLL (0.52) RGS4ALDH1A1MAPTNPSR1LMNA
SCHEMBL303331 0.88 ALDH1A1 (0.51) RGS4ALDH1A1MAPTNPSR1LMNA
SCHEMBL1471652 0.86 HSP90AA1 (0.54) RGS4ALDH1A1MAPTNPSR1LMNA
SCHEMBL1471071 0.85 GAA (0.48) RGS4ALDH1A1MAPTNPSR1LMNA
SCHEMBL1471856 0.84 LMNA (0.59) RGS4ALDH1A1MAPTNPSR1LMNA
SCHEMBL1471831 0.84 LMNA (0.59) RGS4ALDH1A1MAPTNPSR1LMNA
SCHEMBL1473349 0.83 MAPT (0.57) RGS4ALDH1A1MAPTNPSR1LMNA
SCHEMBL1473671 0.83 MGLL (0.51) RGS4ALDH1A1MAPTNPSR1LMNA
SCHEMBL1471051 0.83 MAPT (0.49) RGS4ALDH1A1MAPTNPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US disclosed
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP disclosed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US disclosed
EP-2091531-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT Congenia S.r.l. (IT) 2009-08-26 EP disclosed
WO-2008067863-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CYC1, MTPN, TXN2 RGS4 2661/4885ALDH1A1 800/4885MAPT 1947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.